Cantor Fitzgerald reaffirmed their overweight rating on shares of Vaxart (NASDAQ:VXRT – Free Report) in a research report released on Thursday, Benzinga reports. The firm currently has a $4.00 target price on the biotechnology company’s stock. Vaxart Price Performance Shares of NASDAQ VXRT opened at $0.78 on Thursday. The stock has a market capitalization of […]